Bungler, I understand. Thanks, I didn't know that.
Merck would still have to deliver the substance, do they?
Or would PPHM (say Avid) produce PD-1 themselves just for there pre-clinical trials? How are they ever going to be sure it is the real thing? The Merck patents covering PD-1 will probably give much information but maybe not all parameters (without using a range) and since PD-1 is approved I figured Merck would not yet have to disclose this to any other party (except maybe the FDA) and that every party that does know (e.g. a CRO that worked for Merck) would be under some kind of non-disclosure.
It would of course be great if PPHM didn't need them at all and could just start doing its thing. Pre-clinical done for CTLA-4, then PD-1 and then an approval for the NSCLC PIII so Bavi would be an approved substance for at least one condition.
Next the step to challenge CTLA 4+Bavi against CTLA 4 alone and PD-1+Bavi against PD-1 alone would be easy. The Bavi version would become SOC for the NEW TREATMENTS of cancer!
Market Data 
Markets 
AI
